Key Principles and Recommended Regimens for First-line Antiretroviral Therapy

  • Author: Paul E. Sax, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/5/18 (What's New)

Summary

    Raltegravir vs Efavirenz in Treatment-Naive Patients
    • The phase III STARTMRK trial compared raltegravir with efavirenz, both with emtricitabine/tenofovir DF, in 563 treatment-naive patients
    • At Week 48, the efficacy of raltegravir was noninferior to that of efavirenz, with 86% and 82%, respectively, achieving HIV-1 RNA < 50 copies/mL by intent-to-treat, noncompleter-equals-failure analysis[Lennox 2009]
    • At Week 240, raltegravir was superior to efavirenz with 71% and 61% of patients, respectively, achieving HIV-1 RNA < 50 copies/mL
      Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Coformulated Regimen vs Efavirenz in Treatment-Naive Patients
        Dolutegravir vs Efavirenz in Treatment-Naive Patients
          Considerations for Choosing Efavirenz vs INSTI-based Therapy

          Action required